Diamyd Provides Update on Negotiations to Acquire American Biotechnology Company
Diamyd Medical AB announced that it is making considerable progress in the negotiations to acquire a small American biotechnology company. This acquisition target has clear overlapping interests with Diamyd's licensed GAD-technology platform in the central nervous system (CNS), and is in accordance with the Company's strategy for international expansion. Diamyd previously announced that its Executive Board plans to request approval at the Annual General Shareholders Meeting on December 12th to execute a new stock emission to generate funds for this acquisition.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.